Back

Role of liver disease in management and outcomes of european and asian patients with atrial fibrillation: a report from two regional prospective observational AF registries

28 August 2023 (17:15 - 18:00)
Organised by: Logo
Congress Presentation Part of: Predictors for atrial fibrillation Clinical ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Davide Antonio Mei

Modena Polyclinic Modena University Hospital, Modena (Italy)

7 More presentations in this session

Presentation thumbnail
Epicardial fat can predict the in-atrial thrombus in patients with atrial fibrillation
Doctor M. Tang (CN)
Abstract Slides Video
Presentation thumbnail
A cardiac rehabilitation and those effects using cardiopulmonary exercise testing in patients undergoing catheter ablation for atrial fibrillation
Doctor S. Maeda (Kawasaki, JP)
Abstract Slides Video
Presentation thumbnail
The association of vasoactive agents with postoperative atrial fibrillation after cardiac surgery
Doctor A. Hammer (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Patterns of comorbidities and influence on the natural history of patients with atrial fibrillation: a latent class analysis from a prospective observational european AF registry
Doctor G. Romiti (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Pulmonary hypertension is an adverse risk factor for patients admitted with atrial fibrillation
Doctor M. Kodali (Milwaukee, US)
Abstract Slides Video

Access the full session

Session thumbnail
Predictors for atrial fibrillation

The Event

Event poster

ESC Congress 2023

28 August 2023 17:15 CET
You may be interested in
thumbnail
Congress Presentation
Non-alcoholic fatty liver disease in patients with atrial fibrillation: a report from a global federated health network.
thumbnail
Congress Session
Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations
thumbnail
Congress Presentation
Risk of thromboembolic and haemorrhagic events associated with anticoagulation among 11,355 patients with non-valvular atrial fibrillation and thrombocytopenia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources